Vista Partners Initiates Coverage on American Bio Medica Corporation (NASDAQ: ABMC)

SAN FRANCISCO, Dec. 12 /PRNewswire-FirstCall/ -- Vista Partners announced today that it has initiated coverage on American Bio Medica Corporation (NASDAQ: ABMC - News). Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. Ross Silver of Vista Partners issued the report. For more information and to download the report; please visit the Vista Partners website at www.vistap.com.

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen®, Rapid One®, Rapid TEC®, RDS® InCup® and Rapid TOX(TM) products test for the presence or absence of drugs of abuse in urine, while OralStat® tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

Contact:
Vista Partners LLC
Ross Silver
(415) 738-6229
info@vistap.com